INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
31.10.25 | 15:29
1,700 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,680 | 1,690 | 08:09 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| 23.10. | Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating | 2 | Investing.com | ||
| 15.10. | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.10. | Innate Pharma SA: Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 | 317 | Business Wire | The event will provide clinical perspectives and market outlook for lacutamab, Innate's lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase... ► Artikel lesen | |
| 18.09. | Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy | 4 | Investing.com | ||
| 18.09. | Innate Pharma: Leerink Partners stuft Aktie nach strategischem Schwenk herab | 3 | Investing.com Deutsch | ||
| 17.09. | Innate Pharma S.A. GAAP EPS of -€0.25, revenue of €4.9M | 4 | Seeking Alpha | ||
| 17.09. | Innate Pharma: Strategische Neuausrichtung auf Kernprojekte verlängert Liquiditätsreichweite bis Q3 2026 | 2 | Investing.com Deutsch | ||
| 17.09. | Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway | 1 | Investing.com | ||
| 17.09. | Earnings Call zu Q2 2025: Innate Pharma legt Fokus auf strategische Kern-Assets | 3 | Investing.com Deutsch | ||
| 17.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 17.09. | Innate Pharma H1 Net Loss Shrinks, Plans 30% Workforce Cut, Stock Drops | 1 | RTTNews | ||
| 17.09. | Innate Pharma SA: Innate Pharma Reports First Half 2025 Business Update and Financial Results | 328 | Business Wire | IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and... ► Artikel lesen | |
| 15.09. | Innate Pharma SA: Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event | 289 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate... ► Artikel lesen | |
| 10.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update | 335 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Wednesday, September 17, 2025... ► Artikel lesen | |
| 02.09. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.09. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025 | 377 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 04.08. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025 | 396 | Business Wire | Regulatory news:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 29.07. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.07. | Innate Pharma SA: Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference | 445 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the company's CEO Jonathan Dickinson and COO Yannis Morel will participate... ► Artikel lesen |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,572 | -1,08 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,650 | +0,86 % | Vivoryon Therapeutics N.V. to Present at Upcoming Conferences | Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
Halle (Saale) / Munich, Germany, November 3, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a... ► Artikel lesen | |
| XOMA ROYALTY | 28,200 | 0,00 % | Mural Oncology plc: Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION... ► Artikel lesen | |
| TME PHARMA | 0,094 | 0,00 % | TME Pharma N.V.: TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase | Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announces... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| CANSINO BIOLOGICS | 5,115 | -1,16 % | CANSINOBIO (06185): TERMS OF REFERENCE FOR THE REMUNERATION AND ASSESSMENT COMMITTEE OF THE BOARD | ||
| KARYOPHARM | 5,300 | +3,92 % | Karyopharm Therapeutics Earnings Preview | ||
| MEREO BIOPHARMA | 1,630 | -0,91 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
| ADICET BIO | 0,656 | +0,69 % | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 9,550 | +1,06 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy... ► Artikel lesen | |
| ANNOVIS BIO | 1,766 | -2,86 % | Annovis Bio, Inc. - 8-K, Current Report | ||
| INTEGRA LIFESCIENCES | 10,500 | +0,96 % | Integra LifeSciences Holdings Corporation: Integra LifeSciences Reports Third Quarter 2025 Financial Results | PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,530 | +2,95 % | Neuphoria Therapeutics, Inc.: Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process | BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments... ► Artikel lesen | |
| RHYTHM PHARMACEUTICALS | 98,00 | 0,00 % | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity | - U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- - European Medicines Agency accepts and validates submission for Type... ► Artikel lesen | |
| RECCE PHARMACEUTICALS | 0,216 | 0,00 % | RECCE PHARMACEUTICALS LTD: Quarterly Activities/Appendix 4C Cash Flow Report |
INNATE PHARMA SA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.